Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 4, 2001, Pages 573-586

  Horrigan, J P ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Acetylcholine; Adult; Attention deficit hyperactivity disorder; Dopamine; Drug therapy; Noradrenaline; Psychostimulant

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALTROPANE; AMFEBUTAMONE; AMINEPTINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATTENADE; ATTENTIN; DESIPRAMINE; DEXAMPHETAMINE; DONEPEZIL; DOPAMINE; GLUTAMATE RECEPTOR; GT 2331; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; LONG ACTING DRUG; MANIFAXINE; MEDEVA SR; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PEMOLINE; PEMOLINE MAGNESIUM; PERCEPTIN; PLACEBO; PSYCHOSTIMULANT AGENT; REBOXETINE; SELEGILINE; SLI 381; SPD 420; UNCLASSIFIED DRUG; VENLAFAXINE; 3-METHYL-5-(1-METHYL-2-PYRROLIDINYL)ISOXAZOLE; AMPHETAMINE DERIVATIVE; CARRIER PROTEIN; CENTRAL STIMULANT AGENT; DOPAMINE BINDING PROTEIN; DOPAMINE-BINDING PROTEIN; INDAN DERIVATIVE; ISOXAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SLI381;

ADULT; ANORGASMIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; FEASIBILITY STUDY; HUMAN; HYPERTENSION; LIVER TOXICITY; PATIENT CARE; REVIEW; SEDATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN IRRITATION; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; VERTIGO;

ADULT; AMPHETAMINES; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMAN; INDANS; ISOXAZOLES; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; PIPERIDINES; PYRROLIDINES;

EID: 0035021613     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.4.573     Document Type: Review

References (98)

1. Epidemiology of ADHD in school-age children
2. Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children
3. Attention-deficit/hyperactivity disorder: A life-span perspective
4. Predictors of persistence and remission of ADHD into adolescence: Results from a four-year prospective follow-up study
5. Adults with attention-deficit/hyperactivity disorder: A controversial diagnosis
6. Attention-deficit/hyperactivity disorder in adult life
7. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder
8. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder
9. Neuroimaging in the developmental disorders: The state of the science
10. Treatment of attention-deficit/hyperactivity disorder
11. Genetic basis of attention deficit and hyperactivity
12. ADHD: Current concepts on etiology, pathophysiology and neurobiology
13. Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit/hyperactivity disorder
14. Association of attention deficit disorder and the dopamine transporter gene
15. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism
16. 4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder
17. 4 gene 7-repeat allele and attention deficit hyperactivity disorder
18. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults
19. Problems in the management of attention-deficit-hyperactivity disorder
20. Rating scales in attention-deficit/hyperactivity disorder: Use in assessment and treatment monitoring
21. The Wender Utah Rating Scale: An aid in the retrospective diagnosis of childhood attention deficit disorder
22. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity
23. Dopamine genes and ADHD
24. Dopamine transporter density in patients with attention deficit hyperactivity disorder
25. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder
26. Attention-deficit/hyperactivity disorder overview
27. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder
28. The stimulants revisited
29. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle
30. Attention-deficit/hyperactivity disorder and substance use: Symptom pattern and drug choice
31. Adult attention deficit hyperactivity disorder: Psychological test profiles in a clinical population
32. Psychostimulants and psychiatrists: The Trent Adult Psychiatry Psychostimulant Survey
33. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder
34. Methylphenidate vs. amphetamine: Comparative review
35. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children
36. Pharmacokinetic and pharmacodynamic properties of amphetamine in ADHD children
37. Long-term efficacy and safety of Concerta (OROS methylphenidate HCL) extended release Tablets
38. Stimulant medications
39. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder
40. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults
41. Pemoline for the treatment of cocaine dependence in methadone maintained patients
42. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder
43. Pharmacodynamics of Adderall in adults with attention-deficit/hyperactivity disorder
44. PK/PD analyses of SLI381 in pediatric ADHD
45. The absorption of sustained-release methylphenidate formulation compared to an immediate-release formulation
46. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: A comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine and pemoline
47. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder
48. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults
49. Development of new long-duration stimulant for ADHD: Alza's Concerta
50. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCI) formulation
51. Development and clinical trial testing of Concerta for the treatment of ADHD in children
52. Once-daily, methylphenidate modified-release (MPH MR) treatment of attention-deficit/hyperactivity disorder (ADHD)
53. Methylphenidate: The role of the d-isomer
54. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder
55. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents
56. Sudden death putatively related to desipramine treatment in youth: A fifth case and a review of speculative mechanisms
57. Bupropion treatment of attention-deficit hyperactivity disorder in adults
58. Bupropion sustained release and smoking cessation
59. A prospective safety surveillance study for bupropion sustained release in the treatment of depression
60. A controlled trial of bupropion SR for attention deficit hyperactivity disorder in adults
61. Pediatric pharmacokinetics/pharmacodynamics of GW320659 in attention-deficit/hyperactivity disorder (ADHD)
62. Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder
63. Antidepressant efficacy of venlafaxine
64. Neuropharmacology of venlafaxine
65. An open trial of venlafaxine in adults patients with attention deficit hyperactivity disorder
66. Open-label trial of venlafaxine in adults with attention deficit disorder
67. Venlafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial
68. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine
69. Newer antidepressants: A comparison of tolerability in general practice
70. Efficacy of tomoxetine vs. placebo in pediatric outpatients with ADHD
71. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder
72. Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinson's disease
73. Biotransformation of deprenyl enantiomers
74. Selegiline in ADHD adults: Plasma monoamines and monoamine metabolites
75. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
76. The aphrodisiac effect of (-)deprenyl in male rats
77. Clinical pharmacokinetics and pharmacodynamics of selegiline: An update
78. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration
79. Central nicotine receptor agonists ABT-418, ABT-089 and (-)-nicotine reduce distractibility in adult monkeys
80. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder
81. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors
82. Donepezil in the treatment of Alzheimer's disease
83. Donepezil for Down's syndrome
84. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury
85. Donepezil for Tourette's disorder and ADHD
86. Adjunctive donepezil in attention deficit hyperactivity disorder in youth: Case series
87. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
88. Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depression
89. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: A review
90. Sexual dysfunction with antidepressant agents: Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRIs
91. Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia
92. Pharmacotherapy of adult attention deficit/hyperactivity disorder: A review